Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $19.33 Average Price Target from Analysts

by · The Cerbat Gem

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $19.3333.

Several equities research analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating on shares of Lexeo Therapeutics in a research note on Monday, November 3rd. Raymond James Financial assumed coverage on Lexeo Therapeutics in a research report on Wednesday, December 17th. They set a “strong-buy” rating and a $25.00 price target on the stock. Leerink Partners raised their price objective on Lexeo Therapeutics from $9.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Guggenheim began coverage on Lexeo Therapeutics in a research note on Wednesday, October 15th. They set a “buy” rating and a $30.00 target price for the company. Finally, Cantor Fitzgerald assumed coverage on Lexeo Therapeutics in a research report on Monday, December 1st. They set an “overweight” rating and a $19.00 target price on the stock.

View Our Latest Report on Lexeo Therapeutics

Insider Buying and Selling at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 13,133 shares of the company’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $8.94, for a total transaction of $117,409.02. Following the completion of the transaction, the chief executive officer owned 242,118 shares in the company, valued at $2,164,534.92. This represents a 5.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Tai Sandi See sold 3,888 shares of the firm’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $8.94, for a total transaction of $34,758.72. Following the completion of the transaction, the insider directly owned 65,862 shares in the company, valued at $588,806.28. This represents a 5.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 24,646 shares of company stock valued at $221,037 over the last ninety days. Corporate insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Lexeo Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Nuveen LLC purchased a new stake in shares of Lexeo Therapeutics during the first quarter worth approximately $125,000. AQR Capital Management LLC raised its holdings in Lexeo Therapeutics by 370.0% in the 1st quarter. AQR Capital Management LLC now owns 50,337 shares of the company’s stock valued at $175,000 after acquiring an additional 39,627 shares during the last quarter. Millennium Management LLC lifted its stake in Lexeo Therapeutics by 654.8% in the 1st quarter. Millennium Management LLC now owns 1,071,489 shares of the company’s stock worth $3,718,000 after purchasing an additional 929,538 shares in the last quarter. Acadian Asset Management LLC purchased a new position in Lexeo Therapeutics in the 1st quarter worth approximately $85,000. Finally, Rhumbline Advisers boosted its holdings in shares of Lexeo Therapeutics by 19.8% during the 1st quarter. Rhumbline Advisers now owns 30,192 shares of the company’s stock worth $105,000 after purchasing an additional 4,995 shares during the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Price Performance

Shares of NASDAQ LXEO opened at $9.93 on Friday. The stock has a market capitalization of $724.79 million, a price-to-earnings ratio of -3.68 and a beta of 1.74. The firm’s 50 day simple moving average is $9.49 and its 200-day simple moving average is $6.79. Lexeo Therapeutics has a 12 month low of $1.45 and a 12 month high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.15. Analysts anticipate that Lexeo Therapeutics will post -3.14 earnings per share for the current fiscal year.

About Lexeo Therapeutics

(Get Free Report)

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.

Further Reading